First patients test new cancer drug in early safety trial
NCT ID NCT04242147
Summary
This was an early-stage study to test the safety of a new drug called KD033 in people with advanced solid tumors that had spread or could not be removed by surgery. The main goal was to find a safe dose by giving the drug to small groups of people at increasing levels. Researchers also wanted to see if the drug showed any signs of fighting the cancer and how the body processed it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center - 333 Cottman Avenue - Site 141
Philadelphia, Pennsylvania, 19111, United States
-
Moffitt Cancer Center - Site 102
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Institute - 665 Elm St - Site 062
Buffalo, New York, 14263, United States
-
UCLA Hematology/Oncology, 2020 Santa Monica Boulevard, Suite 600 - Site 042
Santa Monica, California, 90404, United States
-
University of Pittsburgh Medical Center - Hillman Cancer Center - 5150 Centre Avenue, Suite 301 - Site 132
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.